Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 40.34B P/E 59.23 EPS this Y 7.80% Ern Qtrly Grth 14.10%
Income 681.8M Forward P/E 12.74 EPS next Y 6.20% 50D Avg Chg -
Sales 6.26B PEG 1.63 EPS past 5Y 17.70% 200D Avg Chg 10.00%
Dividend N/A Price/Book 3.25 EPS next 5Y 8.49% 52W High Chg -3.00%
Recommedations 2.70 Quick Ratio 3.47 Shares Outstanding 221.02M 52W Low Chg 83.00%
Insider Own 0.27% ROA 10.08% Shares Float 220.65M Beta 1.26
Inst Own 88.02% ROE 4.43% Shares Shorted/Prior -/- Price 182.50
Gross Margin 90.94% Profit Margin 10.89% Avg. Volume 4,222,993 Target Price 177.36
Oper. Margin 47.41% Earnings Date Oct 27 Volume 3 Change 0.00%

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. The company was incorporated in 1992 and is based in Boston, Massachusetts with an additional office in Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.

ALXN Chatroom

User Image macroaxis Posted - 1 week ago

$ALXN - Option Volatility signal: Alexion Pharmaceuticals pin risk is sliding https://www.macroaxis.com/stock-options/ALXN/Alexion-Pharmaceuticals?utm_source=dlvr.it&utm_medium=stocktwits

User Image bigwhalealert Posted - 2 weeks ago

$ALXN BUY/SELL METER Alert Cross 13% +- Technical Analysis https://t8sk.com/ALXN

User Image Newsfilter Posted - 1 month ago

$ALXN Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants - NCT05501717 https://newsfilter.io/a/d4d1af94ed4bfdc8038e91991ea557ae

User Image bigwhalealert Posted - 1 month ago

$ALXN BUY/SELL METER Alert Cross 13% + πŸš€ https://t8sk.com/ALXN

User Image bigwhalealert Posted - 1 month ago

$ALXN - BUY/SELL METER NOW🦍: https://t8sk.com/ALXN- 16% πŸš€

User Image GeorgeTheo Posted - 1 month ago

$SLS Analyst are calling for $200 million in Gps sales for the first AML indication, secondary remission plus $800 million more through an expanded label are plenty good reason for SLS shares to Jump. Do the math Biotech jump like that all the time - look at $CPXX. I remember $ALXN jumped from $4 to $120 twice in a week - settled back in the $30's before running up to a few splits. $SGEN a $4 stock forever, shot up on approval. bounced off $200. This will be Happening Here.

User Image macroaxis Posted - 2 months ago

$ALXN - Alexion options price alert: put open interest is down to 327.0 https://www.macroaxis.com/stock-options/ALXN/Alexion-Pharmaceuticals?utm_source=dlvr.it&utm_medium=stocktwits

User Image streamwars Posted - 3 months ago

$AZN is up, $MREO is way down. Says to me that this "buy out" was just a rumour, designed to pump MREO up above the Nasdaq dollar. Astrazeneca already has a similar / better drug in the pipeline and already has a licensing deal with MREO. They do not need to buy the company. Why would they as they are still paying for the excellent deal they made with $ALXN? I tried to warn you folk at MREO.

User Image Newsfilter Posted - 3 months ago

$ALXN Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants - NCT05428696 https://newsfilter.io/a/23ec9c3ad4d9aead5c2c1fa6340cea45

User Image patatechaude Posted - 3 months ago

$AKTX Soliris ($ALXN now $AZN) for PNH sales @ +$1B and Rachelle brings Nomacopan for PNH back on the table (on top of a rich list of potential rare disease indications). $AKTX could be one of the biggest $XBI gainer of the next few years. $1 is a gift.

User Image patatechaude Posted - 3 months ago

$AKTX New COO starts in July. Rachelle is pumped up by the potential she sees at Akari. The next few months should bring good news. Time to make Akari the Billion$ biotech it’s meant to be. $ALXN waiting to happen.

User Image Trinitrade Posted - 3 months ago

$MREO Even shorts are fake. Scaring retail into selling. $AZN bought out $ALXN just last year ppl and it all started with supossed rumor. How soon we forget. πŸŽ„πŸ’ΈπŸŽ„πŸ’ΈπŸŽ„πŸ’ΈπŸŽ„πŸŒ‹πŸŒ‹πŸš€πŸš€πŸš€

User Image Newsfilter Posted - 3 months ago

$ALXN Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease - NCT05419765 https://newsfilter.io/a/c028bb9d9e767a0ba44ee703d851b3c6

User Image AuphAurinia Posted - 3 months ago

$AUPH Positive news from $BMY acquisition leading market higher $XBI. Until doubt remain on longevity patent, we will stay where we are. Comparable situation happened to $ALXN a year before its acquisition by $AZN

User Image patatechaude Posted - 4 months ago

Time to buy $AKTX if you’re not in yet. $ALXN competitor in the making.

User Image Newsfilter Posted - 4 months ago

$ALXN ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program - NCT05368038 https://newsfilter.io/a/5756197411dfce41bd5b702905ccd146

User Image macroaxis Posted - 4 months ago

$ALXN - Calls open interest is downshifting for Alexion Pharmaceuticals this week https://www.macroaxis.com/stock-options/ALXN/Alexion-Pharmaceuticals?utm_source=dlvr.it&utm_medium=stocktwits

User Image ViractaTrader Posted - 5 months ago

$PBYI This patent infringement lawsuit versus $AZN against Tagrisso probably pushes them to buy Puma Biotechnology for $1 billion in stock. Tagrisso is a $5 billion dollar revenue drug. They will probably need to give $PFE half a billion in cash as well. It's a scratch for AZN if they do this since Puma's drug Neratinib has 8 years of Patent life so $200,000,000 * 8 equals $1.6 billion in revenues. Puma is only trading at $132 million market cap or .65x Revenues. And, the normal takeover equals 5x... So we should be seeing that $24.5 on a takeover in the future. They just threw $775 million to $ALXN and Europeans hate patent lawsuits. Won't end well for AZN if they drag it out. Talked with a broker at Morgan Stanley and he 100% agreed with me.

User Image Newsfilter Posted - 5 months ago

$ALXN A Study of ALXN1840 Administered With And Without Omeprazole In Healthy Adults - NCT05319899 https://newsfilter.io/a/69a926ad11252c772b59d81efaa6b694

User Image Newsfilter Posted - 5 months ago

$ALXN A Study of ALXN1840 Administered With And Without Omeprazole In Healthy Adults - NCT05319912 https://newsfilter.io/a/44732143fecd566da1d86a741cae60ed

User Image Newsfilter Posted - 5 months ago

$ALXN Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria - NCT05314231 https://newsfilter.io/a/5a146f8ba1f73182356bbabc19d8bf1f

User Image Newsfilter Posted - 5 months ago

$ALXN Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants - NCT05307978 https://newsfilter.io/a/9c19caa674378ea551195c889e8f6070

User Image Newsfilter Posted - 6 months ago

$ALXN A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants - NCT05288829 https://newsfilter.io/a/50d330620fe58d35181cdd5d8faa334a

User Image Newsfilter Posted - 6 months ago

$ALXN A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants - NCT05288816 https://newsfilter.io/a/45a0c1cd7bc317449371ad15280f6021

User Image Newsfilter Posted - 6 months ago

$ALXN A Study of a Single Dose of ALXN1210 in Healthy Participants - NCT05288660 https://newsfilter.io/a/41521c039062c44e96bd88a2125241ee

User Image Newsfilter Posted - 6 months ago

$ALXN A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants - NCT05288673 https://newsfilter.io/a/5b6bd40e150a81dca43e91717698018b

User Image STCKPRO Posted - 6 months ago

$ALXN NEW ARTICLE : AstraZeneca to pay US$775mln to settle Alexion patent dispute https://www.stck.pro/news/ALXN/24531477

User Image Newsfilter Posted - 6 months ago

$ALXN Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria - NCT05274633 https://newsfilter.io/a/b20660296426d1ff56e4d329595fdbfb

User Image Newsfilter Posted - 02/28/22

$ALXN Study of ALXN2050 in Participants With Hepatic Impairment - NCT05259085 https://newsfilter.io/a/5605435fbc81063157eb32da06e6a373

User Image Newsfilter Posted - 7 months ago

$ALXN A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants - NCT05254613 https://newsfilter.io/a/ebb21b3fbb7a9b98834dddadf7b4b32e

Analyst Ratings
SVB Leerink Market Perform Mar 23, 21
SVB Leerink Outperform Feb 5, 21
Raymond James Market Perform Jan 8, 21
Truist Securities Hold Dec 16, 20
Citigroup Neutral Dec 15, 20
Credit Suisse Neutral Dec 14, 20
BMO Capital Market Perform Dec 14, 20
Baird Neutral Dec 14, 20
SVB Leerink Outperform Dec 14, 20